Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)-Reference-Cited by-同舟云学术

Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT)

Published:2000-04-26 Issue:9 Volume:25 Page:957-964
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Voso MT,Martin S,Hohaus S,Abdallah A,Schlenk RF,Ho AD,Haas R

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1702336.pdf

Reference24 articles.

1. Rosenberg SA . Karnofsky memorial lecture. The low-grade non-Hodgkin’s lymphomas: challenges and opportunities J Clin Oncol 1985 3: 299–310

2. Horning SJ . Treatment approaches to the low-grade lymphomas Blood 1994 834: 881–884

3. Johnson PW, Rohatiner AZ, Whelan JS et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20 year study from a single center J Clin Oncol 1995 13: 140–147

4. Hiddemann W, Unterhalt M, Herrmann R et al. Mantle cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group J Clin Oncol 1998 16: 1922–1930

5. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin’s lymphoma New Engl J Med 1995 333: 1540–1545

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose Chemotherapy Followed by Autologous and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Follicular Non-Hodgkin's Lymphoma in the Rituximab Era;Tumori Journal;2015-01

2. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation;Annals of Oncology;2013-06

3. Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma;The Korean Journal of Hematology;2012

4. Relevance and Clinical Implications of Tumor Cell Mobilization in the Autologous Transplant Setting;Biology of Blood and Marrow Transplantation;2011-07

5. 90Y Ibritumomab Tiuxetan (Zevalin) Combined With BEAM (Z -BEAM) Conditioning Regimen Plus Autologous Stem Cell Transplantation in Relapsed or Refractory Low-grade CD20-positive B-cell Lymphoma. A GELA Phase II Prospective Study;Clinical Lymphoma Myeloma and Leukemia;2011-04